ArticleHeart rhythm O22026
Efficacy and safety of atrial fibrillation ablation in patients with Marfan syndrome: A multicenter analysis.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Connective tissue disorders and cardiac arrhythmias: genetic pathways, mechanistic bridges, and clinical implications.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with Marfan syndrome (MFS) are at an increased risk of atrial fibrillation (AF) and atrial flutter (AFL), yet data on catheter ablation outcomes in this population remain limited. Objective: This study aimed to evaluate recurrence rates, clinical outcomes, and procedural complications after AF and AFL ablation in patients with MFS. Methods: We conducted a retrospective study of patients with confirmed MFS treated across Mayo Clinic sites from 2018 to 2024. Among 1113 screened patients, 979 had confirmed MFS. After excluding those younger than 18 years and with insufficient follow-up, 209 patients with documented AF or AFL remained, of whom 67 underwent catheter ablation. Collected data included demographics, arrhythmia characteristics, ablation type, recurrence, complications, and echocardiographic findings. Results: Among 67 ablation patients, 41 (61.2%) underwent rhythm-targeted AF ablation, 15 (22.4%) cavotricuspid isthmus ablation, and 11 (16.4%) atrioventricular node ablation. Within the AF ablation group, 26 (63.4%) had paroxysmal AF and 15 (36.6%) persistent AF; 85% also had AFL. Recurrence occurred in 76.9% of patients with paroxysmal AF (median 1.03 years) and in 93.3% of persistent AF (median 0.82 years). Repeat ablation was required in 42.3% and 60%, respectively. Overall, 34 of 41 (82.9%) experienced recurrence, and 20 (48.8%) underwent multiple procedures. Complications occurred in 19 (28.4%), including vascular injury, bleeding, retroperitoneal hemorrhage, pericardial effusion, pulmonary vein stenosis, phrenic nerve injury, and thromboembolic events. Conclusion: In patients with MFS, AF ablation is associated with high recurrence rates, frequent repeat procedures, and notable complication risk. These findings emphasize careful patient selection and vigilant long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.